Tuesday, September 6, 2016
The Pulse on Site Success by Christophe Berthoux
A great deal of emphasis has traditionally been placed on the sponsor-site relationship and the sponsor-CRO relationship; however, given the complexities of the current clinical research environment, these relationships are being redefined. CROs have recognized the importance of developing new approaches in order to ease the administrative burden typically placed on sites.
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, has announced the launch of new drug management modules for its interactive response technology (IRT) system. The advancements are designed to enhance efficiency and drug accountability, while also boosting quality assurance and patient safety in clinical trials.
Mobile health picks up momentum
Leapcure, a provider of patient engagement solutions for clinical trials and pharmaceutical research, has teamed up with Scientist.com, a marketplace for pharmaceutical services, to provide patient recruitment services for users of Scientist.com’s network of 10 pharmaceutical research marketplaces. The partnership will provide white-label, global clinical recruitment services using Leapcure’s smart patient engagement platform.
Medivir has announced that the Board of Directors has tasked the company management to continue the implementation of a separation of the company’s operations into two independent companies, with the intention to obtain a separate listing on First North Premium for the new commercial company based on Medivir’s current pharmaceutical portfolio. The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio.
Vention Medical has opened an additional facility in Ireland to more closely collaborate with customers in the region and accelerate their development initiatives. The new facility will provide medical device design and development services and house Vention’s team of dedicated development professionals.
Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has announced that President Dr. Jean Pierre Wery has moved into the role of chief executive officer.
Incyte has been ranked 4th on Forbes magazine’s 2016 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.
Biothera Pharmaceuticals has announced a collaboration with Merck, known as MSD outside the U.S. and Canada, to expand the companies’ ongoing clinical program evaluating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 inhibitor, in combination with Biothera’s Imprime PGG, a Pathogen Associated Molecular Patterning molecule, or PAMP. Imprime PGG acts as an immunological “ignition switch” enlisting the innate immune system to enhance the therapeutic efficacy of tumor targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies.